© 2020 MJH Life Sciences and OncLive. All rights reserved.
April 15, 2020
David Morris, MD, FACS, discusses overall survival data with apalutamide in prostate cancer.
February 05, 2020
David Morris, MD, FACS, discusses choosing the best agent to treat patients with nonmetastatic castration-resistant prostate cancer.
November 27, 2019
David Morris, MD, FACS, discusses the safety profiles and common adverse events related to the androgen receptor inhibitors apalutamide, enzalutamide, and darolutamide for prostate cancer.